NCT02919683 2026-01-28
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Intensity Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb